Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion

Inclusion Criteria: * Adults (age 18 years and older); * Imaging diagnosis of acute ischemic stroke with anterior circulation large vessel occlusion (including: internal carotid artery, middle cerebral artery M1 and M2, anterior cerebral artery A1 and A2); * Planned to undergo endovascular intervention within 24 hours of symptom onset (or last known well time) according to local guidelines; * Provision of informed consent by the patient or his/her legally authorized representative (or by an appropriate agent according to local requirements). Exclusion Criteria: * ASPECTS score ≤5 on cranial CT imaging; * Pre-existing functional impairment, with mRS score \>2; * Patients who are allergic to PCSK9 inhibitors; * Patients who have received PCSK9 monoclonal antibody within 1 month prior to enrollment or PCSK9 siRNA therapy within 6 months prior to enrollment; * Severe renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73m2 at final screening; * Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 times the upper limit of normal; * Severe, concomitant non-cardiovascular disease expected to reduce life expectancy to less than 3 months; * Pregnant or lactating women; * Patients who are participating in other clinical trials; * Other conditions deemed unsuitable for inclusion in the clinical study by the investigator.